I agree with you 100% Misiu. Once again, leronlimab is straddled with using a sub therapeutic dose in its first patients, and then delaying the initiation of testing the fundamental concept in the study, which is that leronlimab will prime the cancerous process for the effects of an ICI. Leronlimab alone can suppress the cancerous growth through VEGF inhibition, CCR5 blockade and other modalities, but your supposition that an unopposed rise in PD-L1 may outweigh these beneficial effects of leronlimab and make patients (all of whom are very ill) do worse without the intervention of an ICI. We are back to only 2 doses in the critical Covid study. I join with you in your prayers that clearer heads will prevail and that the study in these very ill patients will be designed to help them and many others in their need.